Patents by Inventor Anna Juncker-Jensen

Anna Juncker-Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240241128
    Abstract: Provided herein are methods for determining the chance of a tumor not responding to an anti-cancer therapy (e.g., a T cell-based immunotherapy) based on the presence, density, number, and/or location of certain three-cell structures as described herein. The three-cell structures may comprise a T cell, an immunosuppressive tumor-associated macrophage, and an immunosuppressive regulatory T cell. Such methods may be useful for identifying patients not likely to respond to T cell-based immunotherapy. Also provided herein are methods for determining the prognosis and/or invasiveness of a tumor. The present disclosure also encompasses methods for treating a tumor, as well as kits for performing the methods disclosed herein.
    Type: Application
    Filed: April 8, 2022
    Publication date: July 18, 2024
    Applicants: NeoGenomics Laboratories, Inc., The University of Sheffield
    Inventors: Claire Lewis, Anna Juncker-Jensen, Mate Levente, Nicholas Matthew Stavrou, Mohammed Ridha Moamin, Richard Allen
  • Patent number: 10487078
    Abstract: Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: November 26, 2019
    Assignees: NantBio, Inc., NantOmics, LLC, Nant Holdings IP, LLC
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Oleksandr V. Buzko, Paul Weingarten, Heather McFarlane, Anna Juncker-Jensen, Justin Golovato, Patrick Soon-Shiong, Chunlin Tao, David Ho
  • Publication number: 20180086752
    Abstract: Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 29, 2018
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Sasha Buzko, Paul Weingarten, Heather McFarlane, Anna Juncker-Jensen, Justin Golovato, Patrick Soon-Shiong, Chunlin Tao, David Ho